The results in TIMER2.0 indicated that PTGES3 expression levels significantly correlated with clinical phenotypes of patients in BRCA, KIRP, LIHC, LUAD, and PRAD, which included tumor stage, race, gender, and age (Figure 1D). This evidence concerns the gene PTGES3 and neoplasm.